TY - JOUR
T1 - Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis
T2 - Clinical and biological results from a prospective multicenter study
AU - Chiò, Adriano
AU - Mora, Gabriele
AU - La Bella, Vincenzo
AU - Caponnetto, Claudia
AU - Mancardi, Gianluigi
AU - Sabatelli, Mario
AU - Siciliano, Gabriele
AU - Silani, Vincenzo
AU - Corbo, Massimo
AU - Moglia, Cristina
AU - Calvo, Andrea
AU - Mutani, Roberto
AU - Rutella, Sergio
AU - Gualandi, Francesca
AU - Melazzini, Mario
AU - Scimè, Rosanna
AU - Petrini, Mario
AU - Bondesan, Paola
AU - Garbelli, Silvia
AU - Mantovani, Stefania
AU - Bendotti, Caterina
AU - Tarella, Corrado
AU - Ghiglione, Paolo
AU - Omedé, Paola
AU - Ulla, Marco
AU - Mascolo, Maria
AU - Carlesi, Cecilia
AU - Tonali, Pietro Attilio
AU - Conte, Amelia
AU - Luigetti, Marco
AU - Alimonti, Dario
AU - Onida, Francesco
AU - Bossolasco, Patrizia
AU - Deliliers, Giorgio Lambertenghi
AU - Valentino, Francesca
PY - 2011/2
Y1 - 2011/2
N2 - Granulocyte colony-stimulating factor (G-CSF) induces a transient mobilization of hematopoietic progenitor cells from bone marrow to peripheral blood. Our aim was to evaluate safety of repeated courses of G-CSF in patients with amyotrophic lateral sclerosis (ALS), assessing disease progression and changes in chemokine and cytokine levels in serum and cerebrospinal fluid (CSF). Twenty-four ALS patients entered an open-label, multicenter trial in which four courses of G-CSF and mannitol were administered at 3-month intervals. Levels of G-CSF were increased after treatment in the serum and CSF. Few and transitory adverse events were observed. No significant reduction of the mean monthly decrease in ALSFRS-R score and forced vital capacity was observed. A significant reduction in CSF levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-17 (IL-17) was observed. G-CSF treatment was safe and feasible in a multicenter series of ALS patients. A decrease in the CSF levels of proinflammatory cytokines MCP-1 and IL-17 was found, indicating a G-CSF-induced central anti-inflammatory response.
AB - Granulocyte colony-stimulating factor (G-CSF) induces a transient mobilization of hematopoietic progenitor cells from bone marrow to peripheral blood. Our aim was to evaluate safety of repeated courses of G-CSF in patients with amyotrophic lateral sclerosis (ALS), assessing disease progression and changes in chemokine and cytokine levels in serum and cerebrospinal fluid (CSF). Twenty-four ALS patients entered an open-label, multicenter trial in which four courses of G-CSF and mannitol were administered at 3-month intervals. Levels of G-CSF were increased after treatment in the serum and CSF. Few and transitory adverse events were observed. No significant reduction of the mean monthly decrease in ALSFRS-R score and forced vital capacity was observed. A significant reduction in CSF levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-17 (IL-17) was observed. G-CSF treatment was safe and feasible in a multicenter series of ALS patients. A decrease in the CSF levels of proinflammatory cytokines MCP-1 and IL-17 was found, indicating a G-CSF-induced central anti-inflammatory response.
KW - Amyotrophic lateral sclerosis
KW - Clinical trial
KW - Granulocyte colony-stimulating factor
KW - Hematopoietic stem cells
KW - Neuroinflammation
UR - http://www.scopus.com/inward/record.url?scp=78751665486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751665486&partnerID=8YFLogxK
U2 - 10.1002/mus.21851
DO - 10.1002/mus.21851
M3 - Article
C2 - 21254083
AN - SCOPUS:78751665486
VL - 43
SP - 189
EP - 195
JO - Muscle and Nerve
JF - Muscle and Nerve
SN - 0148-639X
IS - 2
ER -